IGC Pharma Receives Patent Allowance for Novel THC-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

IGC Pharma has received a Notice of Allowance from the USPTO for its patent application US 17/613,909, which is for a proprietary method to treat stammering, stuttering, or Tourette's syndrome with THC and/or CBD. The method combines low doses of atypical antipsychotics with low doses of THC to improve treatment effectiveness while reducing side effects. IGC Pharma plans to move the research to clinical formulations similar to its flagship medication, IGC-AD1, which is currently in Phase 2 clinical trials.

IGC Pharma (NYSE American: IGC) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application US 17/613,909 (IGC510), which covers a proprietary method for treating stammering, stuttering, and Tourette's syndrome using THC and/or CBD. The patent represents a significant intellectual property milestone for the company, which aims to target a substantial global market of approximately 75 million affected individuals.

The therapeutic approach combines low doses of atypical antipsychotics with microdoses of THC and/or CBD, targeting the endocannabinoid system. This strategy aims to optimize efficacy while minimizing the adverse effects typically associated with higher doses of either compound alone. The patent adds to IGC's growing portfolio, which includes treatments for Alzheimer's, pain, and eating disorders.

IGC Pharma plans to advance this research toward clinical formulations similar to its flagship medication, IGC-AD1, which is currently in Phase 2 clinical trials. The microdosing approach is particularly notable as it addresses a critical safety concern with cannabis-based therapeutics by using minimal effective doses of THC, aiming to deliver therapeutic benefits while maintaining a more favorable safety profile than traditional high-dose THC or antipsychotic treatments.

For IGC Pharma, this patent allowance represents not just protection for a novel formulation but potential positioning in multiple neurological disorder markets where current treatment options are limited or carry significant side effect burdens.

References:
[1] https://www.stocktitan.net/news/IGC/igc-pharma-receives-notice-of-allowance-for-novel-thc-microdose-4s1lunvm2myw.html
[2] https://www.biospace.com/press-releases/igc-pharma-expands-calma-phase-2-trial-with-site-at-lynn-health-science-institute-in-oklahoma-city